Steven D. Gore, MD

Professor of Internal Medicine (Hematology); Director of Hematologic Malignancies

Physician Biography

Dr. Gore came to Yale in November 2013 following 23 years on the faculty at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. Dr. Gore is an international authority on myelodysplastic syndromes (MDS) and other forms of leukemia. He is particularly known for his novel clinical and translational trials in MDS and leukemia, using drugs which target epigenetic abnormalities in leukemia cells. He is a leader in the leukemia effort of the Eastern Cooperative Oncology Group and is a member of the MDS committee of the National Cancer Care Network.

Clinical Interests

  • Hematology
  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Hematology

Yale Cancer Center: Hematology Program

Yale Medicine

Board Certifications

  • Internal Medicine AB of Internal Medicine (1987)

  • Medical Oncology AB of Internal Medicine (1989)

Clinical Trials

Conditions Study Title
Leukemia, other An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of DCLL9718S in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Patients With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Myeloid and Monocytic Leukemia A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)
Myeloid and Monocytic Leukemia The National Myelodysplastic Syndromes Natural History Study
Myeloid and Monocytic Leukemia A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination With 5-Azacytidine (5AC, NSC 102816) in Elderly Patients With Acute Myeloid Leukemia (AML)
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia An Open-label Phase 1b Study Of Pf-04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Higher-risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, Or Chronic Myelomonocytic Leukemia
Myeloid and Monocytic Leukemia A Phase 1, Open-label, Dose Finding Study of CC-90009 in Subjects With Relapsed, Refractory Acute Myeloid Leukemia
Leukemia, other Assessment of Quality of Life, Prognostic Understanding, and Perceived Goals of Care in Patients with Leukemia
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Leukemia, other A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Myeloid and Monocytic Leukemia A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents
Myeloid and Monocytic Leukemia A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation
Myeloid and Monocytic Leukemia A Phase 2/3 Multicenter, Open-label, 3-arm, 2-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Non-Hodgkin's Lymphoma A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Non-Hodgkin's Lymphoma A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Leukemia, not otherwise specified, Myeloid and Monocytic Leukemia A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Myeloid and Monocytic Leukemia A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine
Myeloid and Monocytic Leukemia Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Myeloid and Monocytic Leukemia A Phase 1b/2 Open-label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Leukemia, other A Phase I, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Edit this profile

Contact Info

Steven D. Gore, MD
Patient Care Location
Yale Cancer Center-YNHHYale New Haven Hospital
20 York Street, Ste 7th Floor

New Haven, CT 06510
View on map...
Mailing Address
Hematology25 York Street
PO Box 208028

New Haven, CT 06520-8028

Curriculum Vitae